Top experts discuss the most important takeaways and data to come out of this year’s ASCO Annual Meeting in ovarian and endometrial cancer.
Related to this article
Selinexor maintenance failed to significantly improve PFS vs placebo in TP53 wild-type advanced or recurrent endometrial cancer in the phase 3 XPORT-EC-042 trial.
Advertisement
Advertisement
Trending on OncLive
1
FDA-Approved ADCs Prompt the Need for Revisions to the Breast Cancer Management Roadmap
2
Dr Mulvey on Real-World Treatment Discontinuation Data for First-Line BTK Inhibitors in CLL
3
Dr Cohen on Phase 1 Efficacy Data for Cevostamab in R/R Myeloma
4
Docirbrutinib Yields High Response Rates in MCL and CLL
5